Dynavax Reports Upbeat Test Results By: MarketMinute.com Stock News June 03, 2009 at 17:23 PM EDT Dynavax Technologies Corp. (Nasdaq: DVAX) reported upbeat Phase III results for its hepatitis B vaccine Heplisav sending the stock price soaring 45 cents to close at $1.86.